about
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signalingClinical implications of genome-wide DNA methylation studies in acute myeloid leukemia.Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma.Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.Inhibition of MicroRNA-149-5p Induces Apoptosis of Acute Myeloid Leukemia Cell Line THP-1 by Targeting Fas Ligand (FASLG).Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.Antibody-Based Treatment of Acute Myeloid Leukemia.Cordycepin induces apoptosis of human acute monocytic leukemia cells via downregulation of the ERK/Akt signaling pathway.A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic RegulatorsHigh-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.Preclinical Antileukemia Activity of Tramesan: A Newly Identified Bioactive Fungal Metabolite.The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada.Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine.Flavopiridol Protects Bone Tissue by Attenuating RANKL Induced Osteoclast Formation.Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side.
P2860
Q33889152-733F46B0-1EAF-4884-BA50-0A4F9BE192AFQ37607838-9279163E-13C7-481A-8CA4-F8C11411F601Q37622957-08D88AA7-4616-49E0-BE16-C428DEBDE5AFQ37699202-321EB699-5F67-484D-9CB0-49E128B7138FQ38636162-45B67F38-D3FC-4887-B312-1EE6B2AED96DQ38724417-2ACBB9DE-E292-482C-ADD6-F7C3F103C673Q38909416-312428CE-ED39-44BA-A233-7545151BA5D6Q38979277-F7A121F4-C1DE-4F91-916B-39A32F681B68Q41623491-596B81B4-460D-405C-8509-ED0C21CAE48BQ42764236-38AC5C29-68B3-4826-A301-C081A7F134E5Q45120868-DC1ED85E-0DD7-4B9B-A70D-9C7ECA41BADCQ47141076-D50052EE-E840-48F9-9B8A-D55776493DDDQ47579728-C08FB9A0-37D4-4774-9A9C-0D91F5324DA3Q48137679-F6F5DB91-80AE-456F-A9F2-F586FD1AC20EQ48253128-130D84D2-9B43-4148-8816-3E4686515B52Q54978831-4F294CB8-8EC9-45A0-B256-25962B8E47A2Q55503143-60731D1E-F50A-40A3-9A1F-BD95FAEF5847
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Update on rational targeted therapy in AML
@ast
Update on rational targeted therapy in AML
@en
Update on rational targeted therapy in AML
@nl
type
label
Update on rational targeted therapy in AML
@ast
Update on rational targeted therapy in AML
@en
Update on rational targeted therapy in AML
@nl
prefLabel
Update on rational targeted therapy in AML
@ast
Update on rational targeted therapy in AML
@en
Update on rational targeted therapy in AML
@nl
P2860
P3181
P1433
P1476
Update on rational targeted therapy in AML
@en
P2093
Danielle Shafer
Steven Grant
P2860
P304
P3181
P356
10.1016/J.BLRE.2016.02.001
P407
P577
2016-07-01T00:00:00Z